文献速递骨软组织肉瘤与黑色素瘤

高危软组织肉瘤辅助化疗与术后放疗:SSG XX研究

Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX).
PubMed 文献 · Eur J Cancer · 2018-06-19

这项前瞻性非随机研究纳入150例按形态学标准定义的高危软组织肉瘤患者,给予多柔比星联合异环磷酰胺辅助化疗及术后加速放疗;5年无转移生存率为70.4%,5年总生存率为76.1%,局部复发率为14.0%,毒性中等且无治疗相关死亡。

要点

  • 高危定义:FNCLCC II-III级且伴血管侵犯或至少两项(肿瘤≥8.0cm、浸润性生长、坏死)。
  • 5年无转移生存70.4%,5年总生存76.1%,局部复发率14.0%。
  • 肿瘤大小、深部位置及剂量强度<80%对生存有负面影响。

核心结论

  • 在具有明确不良预后因素的高危软组织肉瘤患者中,与类似历史对照组相比,辅助化疗显示出获益。
  • 血管侵犯、肿瘤大小、生长模式和坏死可能用于识别需要辅助化疗的患者。

研究设计与样本

  • 前瞻性非随机研究,纳入150例符合标准的高危软组织肉瘤患者。
  • 高危定义为FNCLCC II-III级且伴血管侵犯或至少两项:肿瘤大小≥8.0cm、浸润性生长、坏死。
  • 干预为6周期多柔比星(60mg/m2)联合异环磷酰胺(6g/m2),术后加速放疗安排在第3和第4周期之间。

主要发现

  • 无转移生存中位随访3.9年(范围0.2-8.7),5年无转移生存率为70.4%(95%CI:63.1-78.4)。
  • 局部复发率为14.0%(95%CI:7.8-20.2)。
  • 总生存中位随访4.4年(范围0.2-8.7),5年总生存率为76.1%(95%CI:68.8-84.2)。
  • 肿瘤大小、深部位置和剂量强度<80%对生存有负面影响。
  • 毒性中等,无治疗相关死亡。

关键数值与推荐

  • 高危软组织肉瘤定义:FNCLCC II-III级且伴血管侵犯或至少两项(肿瘤大小≥8.0cm、浸润性生长、坏死)。
  • 辅助化疗方案:多柔比星60mg/m2联合异环磷酰胺6g/m2,共6周期。
  • 术后加速放疗安排在第3和第4周期之间。

临床怎么用

  • 对于符合高危形态学标准的软组织肉瘤患者,可考虑辅助多柔比星联合异环磷酰胺化疗。
  • 术后加速放疗可与化疗交替进行,安排在化疗第3和第4周期之间。
  • 应关注肿瘤大小、深部位置及剂量强度,剂量强度<80%可能对生存产生负面影响。

局限性

  • 研究为非随机设计,结论基于与历史对照组的比较。
  • 样本量为150例,随访时间有限(中位随访3.9-4.4年)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the outcome following adjuvant doxorubicin and ifosfamide in a prospective non-randomised study based on a soft tissue sarcoma (STS) patient subgroup defined by specific morphological characteristics previously shown to be at a high-risk of metastatic relapse. The expected 5-year cumulative incidence of metastases in patients with this risk profile has previously been reported to be about 50% without adjuvant chemotherapy. METHODS: High-risk STS was defined as high-grade morphology (according to the Fédération Nationale des Centres de Lutte Contre le Cancer [FNCLCC] grade II-III) and either vascular invasion or at least two of the following criteria: tumour size ≥8.0 cm, infiltrative growth and necrosis. Six cycles of doxorubicin (60 mg/m2) and ifosfamide (6 g/m2) were given. Postoperative accelerated radiotherapy was applied and scheduled between cycles 3 and 4. RESULTS: For the 150 eligible patients, median follow-up time for metastases-free survival was 3.9 years (range 0.2-8.7). Five-year metastases-free survival (MFS) was 70.4% (95% confidence interval [CI]: 63.1-78.4) with a local recurrence rate of 14.0% (95% CI: 7.8-20.2). For overall survival (OS), the median follow-up time was 4.4 years (range: 0.2-8.7). The five-year OS was 76.1% (95% CI: 68.8-84.2). Tumour size, deep location and reduced dose intensity (<80%) had a negative impact on survival. Toxicity was moderate with no treatment-related death. CONCLUSIONS: A benefit of adjuvant chemotherapy, compared to similar historical control groups, was demonstrated in STS patients with defined poor prognostic factors. Vascular invasion, tumour size, growth pattern and necrosis may identify patients in need of adjuvant chemotherapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Sundby Hall K, Bruland ØS, Bjerkehagen B, et al. Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX). Eur J Cancer. 2018. PMID: 29929092. doi:10.1016/j.ejca.2018.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。